PMID- 29754277
OWN - NLM
STAT- MEDLINE
DCOM- 20190909
LR  - 20191008
IS  - 1432-0827 (Electronic)
IS  - 0171-967X (Print)
IS  - 0171-967X (Linking)
VI  - 103
IP  - 4
DP  - 2018 Oct
TI  - Proton Pump Inhibitor Use, H(2)-Receptor Antagonist Use, and Risk of Incident 
      Clinical Vertebral Fracture in Women.
PG  - 380-387
LID - 10.1007/s00223-018-0432-2 [doi]
AB  - The few prospective studies examining the relation between proton pump inhibitor 
      (PPI) use and risk of vertebral fracture (VF) suggest a higher risk, but the 
      magnitude of the association has been inconsistent. Moreover, no prospective 
      studies have examined the association between substantially longer duration of 
      PPI use and VF risk. Our objective was to determine the association between PPI 
      use, H(2)RA use, and incident clinical VF in women. We conducted a prospective 
      study in 55,545 women participating in the Nurses' Health Study. PPI and H(2)RA 
      use was assessed by questionnaire every 4 years. Self-reports of VF were 
      confirmed by medical record. Our analysis included 547 incident VF cases 
      (2002-2014). The multivariate adjusted relative risk (MVRR) of VF for women 
      taking PPIs was 1.29 (95% CI 1.04-1.59) compared with non-users. Longer duration 
      of PPI use was associated with higher VF risk (MVRR 1.16 [0.90-1.49] for 
      < 4 years; 1.27 [0.93-1.73] for 4-7.9 years; 1.64 [1.02-2.64] for >/= 8 years; 
      p(trend) = 0.01). The MVRR of VF for women taking H(2)RAs was 1.22 (0.90-1.67) 
      compared with non-users. Longer duration of H(2)RA use was not associated with VF 
      risk (MVRR 1.16 [0.88-1.53] for < 4 years; 0.98 [0.60-1.59] for >/= 4 years; 
      p(trend) = 0.72). PPI use is independently associated with a modestly higher risk 
      of VF and the risk increases with longer duration of use. There was no 
      statistically significant association between H(2)RA use and VF risk. Our 
      findings add to the growing evidence suggesting caution with PPI use, 
      particularly with longer duration of use.
FAU - Paik, Julie M
AU  - Paik JM
AD  - Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard 
      Medical School, Boston, MA, USA. jmpaik@bwh.harvard.edu.
AD  - Renal Division, Department of Medicine, Brigham and Women's Hospital and Harvard 
      Medical School, Boston, MA, USA. jmpaik@bwh.harvard.edu.
AD  - Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, 
      MA, USA. jmpaik@bwh.harvard.edu.
AD  - New England Geriatric Research Education and Clinical Center, VA Boston 
      Healthcare System, Boston, MA, USA. jmpaik@bwh.harvard.edu.
AD  - Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard 
      Medical School, 181 Longwood Avenue, Room 432, Boston, MA, 02115, USA. 
      jmpaik@bwh.harvard.edu.
FAU - Rosen, Harold N
AU  - Rosen HN
AD  - Endocrinology Division, Beth Israel Deaconess Medical Center and Harvard Medical 
      School, Boston, MA, USA.
FAU - Gordon, Catherine M
AU  - Gordon CM
AD  - Division of Adolescent and Transition Medicine, Cincinnati Children's Hospital 
      Medical Center, Cincinnati, OH, USA.
AD  - University of Cincinnati College of Medicine, Cincinnati, OH, USA.
FAU - Curhan, Gary C
AU  - Curhan GC
AD  - Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard 
      Medical School, Boston, MA, USA.
AD  - Renal Division, Department of Medicine, Brigham and Women's Hospital and Harvard 
      Medical School, Boston, MA, USA.
AD  - Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, 
      MA, USA.
LA  - eng
GR  - K23 DK100447/DK/NIDDK NIH HHS/United States
GR  - K24 DK091417/DK/NIDDK NIH HHS/United States
GR  - UM1 CA186107/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20180512
PL  - United States
TA  - Calcif Tissue Int
JT  - Calcified tissue international
JID - 7905481
RN  - 0 (Histamine H2 Antagonists)
RN  - 0 (Proton Pump Inhibitors)
SB  - IM
MH  - Adult
MH  - Cohort Studies
MH  - Female
MH  - Histamine H2 Antagonists/*adverse effects
MH  - Humans
MH  - Incidence
MH  - Middle Aged
MH  - Prospective Studies
MH  - Proton Pump Inhibitors/*adverse effects
MH  - Risk Factors
MH  - Spinal Fractures/*epidemiology
MH  - Surveys and Questionnaires
PMC - PMC6231994
MID - NIHMS967503
OTO - NOTNLM
OT  - H2-receptor antagonist
OT  - Nurses' health study
OT  - Prospective study
OT  - Proton pump inhibitor
OT  - Vertebral fracture
COIS- Conflicts of Interest: All authors state that they have no conflicts of interest.
EDAT- 2018/05/14 06:00
MHDA- 2019/09/10 06:00
PMCR- 2019/10/01
CRDT- 2018/05/14 06:00
PHST- 2018/03/21 00:00 [received]
PHST- 2018/05/08 00:00 [accepted]
PHST- 2018/05/14 06:00 [pubmed]
PHST- 2019/09/10 06:00 [medline]
PHST- 2018/05/14 06:00 [entrez]
PHST- 2019/10/01 00:00 [pmc-release]
AID - 10.1007/s00223-018-0432-2 [pii]
AID - 10.1007/s00223-018-0432-2 [doi]
PST - ppublish
SO  - Calcif Tissue Int. 2018 Oct;103(4):380-387. doi: 10.1007/s00223-018-0432-2. Epub 
      2018 May 12.